Device injection plus chemotherapy for locally advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new injectable treatment (NRT6008) given with standard chemotherapy for people whose pancreatic cancer cannot be removed by surgery. The goal is to see if it helps control the tumor better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old
- You have a type of pancreatic cancer called ductal adenocarcinoma that is locally advanced (hasn't spread far) and cannot be surgically removed
- You have a single tumor in the pancreas that measures from 2 to 6 cm across
- You are able to care for yourself (a score of 0 or 1 on a standard daily activity scale)
- You have not received any prior cancer treatment for this pancreatic cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
This study tests a new approach for locally advanced pancreatic cancer that hasn't spread. It combines precise high-dose radiation with an experimental immunotherapy (PCX12) injected directly into the tumor to see if it's safe and tolerable.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Hear when a new Unresectable Locally Advanced Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.